AAN 2025 | Biomarkers in MS: clinical implementation and barriers
Enric Monreal, MD, PhD, Ramón y Cajal Hospital, Madrid, Spain, discusses the role of biomarkers in transitioning from evidence-based medicine to personalized medicine in multiple sclerosis. Dr Monreal highlights the potential of biomarkers to predict prognosis and inform treatment decisions, but notes that there are still some barriers to clinical implementation. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s a need in general in neurology but also in multiple sclerosis to move from an evidence-based medicine to a more personalized medicine and I think biomarkers is the first step because it’s something that we can measure in patients and it’s easy to implement in clinical practice so by using several biomarkers, especially at disease onset, whenever the neurological damage is low, they could help us predict the prognosis of a single patient and we can decide which treatment is better...
There’s a need in general in neurology but also in multiple sclerosis to move from an evidence-based medicine to a more personalized medicine and I think biomarkers is the first step because it’s something that we can measure in patients and it’s easy to implement in clinical practice so by using several biomarkers, especially at disease onset, whenever the neurological damage is low, they could help us predict the prognosis of a single patient and we can decide which treatment is better. So, they are very useful for treatment optimization and treatment selection at disease onset. Currently, these biomarkers are mainly under investigation. Some of them are starting to be available in clinical practice, but there are several barriers, especially when measuring neurofilaments and GFAP, because we need a technique, which is simoa, which is quite expensive, but there are several platforms that are currently trying to correlate with this simoa that are currently available in most of the hospitals. So I think that in the short future they would be available for most of the physicians to implement for their patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
